相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk factors for and the prevention of acute kidney injury after abdominal surgery
Yongbo An et al.
SURGERY TODAY (2018)
Borderline resectable pancreatic cancer. Challenges and controversies
Luis Sabater et al.
CANCER TREATMENT REVIEWS (2018)
Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases
Sven H. Loosen et al.
Oncotarget (2018)
Acute kidney injury in major abdominal surgery: incidence, risk factors, pathogenesis and outcomes
Joana Gameiro et al.
ANNALS OF INTENSIVE CARE (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Circulating Levels of Osteopontin Predict Patients' Outcome after Resection of Colorectal Liver Metastases
Sven H. Loosen et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery
Jana C. Mossanen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma
Sven H. Loosen et al.
JOURNAL OF HEPATOLOGY (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
A preoperative score to predict early death after pancreatic cancer resection
Gianpaolo Balzano et al.
DIGESTIVE AND LIVER DISEASE (2017)
Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells
Susanna W. L. de Geus et al.
BIOMARKER INSIGHTS (2017)
Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease
Felix C. Popp et al.
BMC CANCER (2017)
Long-term survival after resections for pancreatic ductal adenocarcinoma. Single centre study
Martin Lovecek et al.
BIOMEDICAL PAPERS-OLOMOUC (2016)
uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R
Michaela C. Huber et al.
BMC CANCER (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
suPAR: The unspecific marker for disease presence, severity and prognosis
Jesper Eugen-Olsen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Impact of preoperative asymptomatic renal dysfunction on clinical course after pancreatoduodenectomy
Minako Nagai et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2015)
Soluble Urokinase Receptor and Chronic Kidney Disease
Salim S. Hayek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis
Matthias Unseld et al.
THROMBOSIS AND HAEMOSTASIS (2015)
The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation
Marco Genua et al.
GUT (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma
Athina Chounta et al.
LIVER INTERNATIONAL (2015)
uPAR Induces Expression of Transforming Growth Factor beta and Interleukin-4 in Cancer Cells to Promote Tumor-Permissive Conditioning of Macrophages
Jingjing Hu et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
Effect of Preoperative Renal Insufficiency on Postoperative Outcomes after Pancreatic Resection: A Single Institution Experience of 1,061 Consecutive Patients
Malcolm H. Squires et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2014)
Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure
Alexander Koch et al.
LIVER INTERNATIONAL (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer
Evren Fidan et al.
MEDICAL ONCOLOGY (2013)
Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review
Yara Backes et al.
INTENSIVE CARE MEDICINE (2012)
Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
Jan Budczies et al.
PLOS ONE (2012)
Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges
Hilde R. H. de Geus et al.
CLINICAL KIDNEY JOURNAL (2012)
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis
Changli Wei et al.
NATURE MEDICINE (2011)
Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients
Alexander Koch et al.
CRITICAL CARE (2011)
Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation
Brian M. Connolly et al.
BLOOD (2010)
suPAR: The molecular crystal ball
Maria Thuno et al.
DISEASE MARKERS (2009)
Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling
Aiqun Xue et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Analysis of mortality rates for pancreatic cancer across the world
D. Hariharan et al.
HPB (2008)
Etiology-dependent molecular mechanisms in human hepatocarcinogenesis
Christof Schlaeger et al.
HEPATOLOGY (2008)
Perioperative increases in serum creatinine are predictive of increased 90-day mortality after coronary artery bypass graft surgery
Jeremiah R. Brown et al.
CIRCULATION (2006)
Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?
N Montuori et al.
THROMBOSIS AND HAEMOSTASIS (2005)
EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma
D Liu et al.
CANCER CELL (2002)
分享论文
